Vol.23 No.5

Original Article

Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic joints

Authors

Daisuke Takahashi1, 2 , Tokifumi Majima1 , Tomohiro Onodera2 , Yasuhiko Kasahara2 , Masahiro Inoue2 , Toru Irie2 , Toshiyuki Kasemura2

  • Department of Joint Replacement and Tissue Engineering, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan
  • Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, Japan
Received:

28 March 2012

Accepted:

3 September 2012

Published online:

22 September 2012

Full Text

PDF　(member's only)

Abstract

Objectives Non-steroidal anti-inflammatory drugs play a
major role in the management of osteoarthritis (OA).
However, it remains unknown whether these drugs affect
cartilage and synovial metabolism in osteoarthritic joints.
The aim of this study was to evaluate the effects of a
selective cyclooxygenase (COX)-2 inhibitor, celecoxib, on
synovial fluids and tissues in severely osteoarthritic knees.
Methods Patients were randomized into three groups and
medicated two weeks prior to total knee arthroplasty with
celecoxib, diclofenac sodium, or no medication (control).
We checked for the presence of matrix metalloproteinase-3
(MMP-3), tumor necrosis factor-a (TNF-a), interleukin-1b
(IL-1b), and hyaluronic acid (HA) in the synovial fluids of
all three groups.
Results MMP-3 significantly decreased in the celecoxibtreated
patients (p = 0.0031). On the other hand, there
were no significant differences among the three groups in
their TNF-a and IL-1b levels. HA in the joint fluid was
significantly increased in the diclofenac-treated group,
while HA was not changed in the celecoxib-treated
patients.
Conclusions Our study suggests that celecoxib did not
affect the level of HA in the joint fluid in the knee in severe
OA, in contrast to the effect of the dual COX inhibitor.

Key words

Celecoxib, Osteoarthritis, Hyaluronic acid